Synaptogenix (NASDAQ:TAOX) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Synaptogenix (NASDAQ:TAOX) from a hold rating to a sell rating in a report published on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX stock opened at $4.41 on Friday. The stock has a fifty day moving average price of $3.86 and a 200 day moving average price of $4.34. The stock has a market cap of $32.99 million, a PE ratio of -1.15 and a beta of 1.73. Synaptogenix has a 1 year low of $3.07 and a 1 year high of $10.00.

Synaptogenix (NASDAQ:TAOX) last posted its earnings results on Thursday, August 13th. The company reported ($1.83) earnings per share for the quarter. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%. The firm had revenue of $0.09 million during the quarter.

About Synaptogenix

Synaptogenix, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc and adopted the Synaptogenix name as part of a corporate rebranding.